Lastly, besides dabrafenib, the use of vemurafenib has also caused persistent and marked tumor shrinkage (>60% for 11 months) in a recurrent BRAF p.V600E-mutated ameloblastoma patient73. This evidence concerns the gene BRAF and neoplasm.